


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Serial No: 10/751,354 **Confirmation No.** 2231
Date Filed: January 5, 2004
Application Title: Active Esters Of N-Substituted Piperazine Acetic Acids,
Including Isotopically Enriched Versions Thereof
Applicants: Dey et al.
Group Art Unit: 1624
Examiner: Ebenezer O. Sackey
Action Type: Office Action – Non Final
Action Date: March 26, 2007

Certificate of Facsimile Transmission Pursuant to:
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the USPTO via EFS-web on this 27th day of August, 2007.


Brian D. Gildea, Reg. No. 39,995

Interview Summary under 37 C.F.R. § 1.560

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir or Madam:

In accordance with 37 C.F.R. § 1.560, entry of the following summary of the discussion between Examiner Sackey and attorney Gildea is requested.

On August 27, 2007, Brian Gildea (Reg. No. 39,995) and Examiner Sackey discussed the response to the restriction requirement as filed on September 26, 2006. In particular, reference was made to newly added claims 50-54. As discussed in the response, these claims (as filed on September 26, 2006) were the same or similar to claims on file in other applications filed on the same day (or which claim priority to applications filed on the same day) naming a common inventor but were added in this application in order to obtain an opinion from the Office as to whether or not restriction between the claims is proper in anticipation of the implementation of new rules of practice with respect to continuation applications.

After a discussion of the claims, Examiner Sackey indicated that he is likely to find that restriction is proper wherein each of claims 50-53 would constitute independently patentable subject matter.

Aug 27, 2007
Date

Respectfully submitted
on behalf of Applicants,

Brian D. Gildea
Brian D. Gildea; Reg. No. 39,995